Key Insights Infographic: Managed Care Considerations on the Emerging Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma

Expert Faculty Presenters:

P. Connor Johnson, MD
Attending Oncologist
Massachusetts General Hospital Center for Lymphoma

Click here for biography

Ryan Haumschild, PharmD, MS, MBA
Director of Pharmacy Services
Emory Healthcare and Winship Cancer Institute

Click here for biography

Gary M. Owens, MD
President
Gary Owens Associates, Inc.

Click here for biography

Fadia T. Shaya, PhD, MPH, FAMIA
Distinguished University Professor
Population Health and Data Science
Executive Director, Behavioral Health Resources and Technical Assistance Program
Department of Practice, Sciences, and Health Outcomes Research
University of Maryland School of Pharmacy
Co-Director of Informatics - Innovation, Dissemination, and Implementation
Institute for Clinical and Translational Research
University of Maryland Baltimore

Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
The expanding array of therapeutic strategies for Non-Hodgkin's Lymphoma (NHL) poses an ongoing challenge in optimal treatment selection and sequencing. Despite notable advancements in disease management and patient survival, many individuals still face disease relapse or encounter treatment-limiting toxicities. Bispecific antibodies (BsAbs) employ elements from diverse antibodies to offer targeted therapeutic approaches, particularly for hematologic malignancies like lymphomas. As clinical evidence supporting the use of BsAbs in hematologic malignancies continues to emerge, managed care pharmacists will need to identify formulary and utilization management strategies that effectively incorporate BsAbs into the current treatment armamentarium. Leverage the expertise of this interactive multistakeholder panel discussion to understand the role of emerging innovative treatments, optimize outcomes, and enhance the care of patients with relapsed/refractory NHL.

Educational Objectives
After completing this activity, the participant should be better able to:

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-116-H01-P
Type of Activity:
Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Name of Faculty Reported Financial Relationship
P. Connor Johnson, MD Consultant/Advisor/Speaker: AstraZeneca, AbbVie, Bristol Myers Squibb, Incyte, Seagen, ADC Therapeutics
Researcher: AstraZeneca, Incyte
Ryan Haumschild, PharmD, MS, MBA Nothing to disclose.
Gary M. Owens, MD Consultant/Advisor/Speaker: Regeneron, Sanofi, Baxter
Independent Contractor: Applied Therapeutics, Arrowhead Pharmaceuticals
Fadia T. Shaya, PhD, MPH, FAMIA Nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.